BRAXF - Braxia gets SAP Canada approval to provide psilocybin-assisted therapy for depression

Braxia Scientific (OTCPK:BRAXF) said on Friday that Canada had approved its application to the Special Access Program (SAP) to provide psilocybin-assisted psychotherapy for a patient with Major Depressive Disorder in Ontario. This is the company's first psilocybin-assisted therapy treatment approval. The approval comes after Health Canada's SAP amended to include access to psychedelic compounds on a case-by-case basis outside of clinical trials on January 5th, 2022. "Being among the first to begin delivering psilocybin-assisted therapy treatments in Canada last year through our clinical trial, we have developed and optimized the infrastructure, including rigorous training for our therapists through our Braxia Institute, to provide a positive patient experience while optimizing outcomes," said Joshua Rosenblat, the company's Chief Medical and Scientific Officer.

For further details see:

Braxia gets SAP Canada approval to provide psilocybin-assisted therapy for depression